Introduction
============

Many intracellular organelles, including the endoplasmic reticulum (ER), actively sequester calcium ions \[[@b1]\]. Transient loss of Ca^2+^ from the ER is an inherent consequence of intracellular Ca^2+^ signalling. However, dysregulation of ER Ca^2+^ homeostasis also occurs pathologically following exposure to toxic insults, ischemia and trauma \[[@b2]\]. Alteration (be it of physiological or pathological origin) in free \[Ca^2+^\] within these internal Ca^2+^ storage compartments is often sensed and translated into downstream signalling activities, such as ER stress responses or engagement of store-dependent Ca^2+^ entry channels \[[@b3]\].

In a previous report from our laboratory, we showed that cAMP could become elevated in the cytosol of certain cell types following depletion of Ca^2+^ from intracellular stores (principally the ER), but this increase in cAMP did not depend whatsoever on the corresponding changes in cytosolic \[Ca^2+^\]. The increase in cAMP, rather, directly mirrored the decrease in free \[Ca^2+^\] inside the ER lumen and required a transmembrane ER Ca^2+^ sensor, STIM1 \[[@b4]\].

STIM1 has been shown to translocate from the bulk ER to specialized ER/plasma membrane junctions following store depletion \[[@b5]--[@b7]\]. STIM1 has also been firmly established to interact with Orai1, the pore-forming unit of a plasma membrane channel that permits Ca^2+^ entry from the extracellular environment \[[@b8]--[@b11]\]. Activation of Orai1 (and possibly other channels) *via* STIM1 allows a sustained Ca^2+^ signal, and refilling of the store. This ubiquitous, widely studied phenomenon known as 'store-operated Ca^2+^ entry' is activated by any manoeuvre that lowers the free \[Ca^2+^\] in the ER lumen \[[@b12]\].

In our studies on ER-dependent cAMP signalling, we found that silencing STIM1 or preventing its translocation reduced cAMP production caused by treatments that lower the levels of free Ca^2+^ within the ER. Because of the many parallels with store-operated Ca^2+^ entry, we named this process 'Store-Operated cAMP Signalling' (SOcAMPS). So far SOcAMPS has been described in several cell types, notably in NCM460 cells \[[@b4]\], a model of normal colonic crypt epithelial cells \[[@b13]\] and CaLu-3 cells (normal human airway epithelia cells) \[[@b14]\]. Although the physiological meaning of SOcAMPS in NCM460 cells is not known, in CaLu-3 this process has been shown to participate in cAMP-dependent chloride and fluid secretion induced by Ca^2+^-mobilizing products secreted from the bacterium *Pseudomonas aeruginosa*. This mechanism may contribute to airway clearance during bacterial infection. Using a model of mouse cholangiocytes, Spirli and colleagues also recently implicated SOcAMPS in the pathogenesis of polycystic liver disease \[[@b15]\]. Interestingly, certain other cells types, such as HeLa cells, appear to lack SOcAMPS \[[@b4]\]. This suggests that a specific panel of proteins must be expressed for SOcAMPS to be operational.

A pathway that links ER Ca^2+^ to cAMP signalling could have extremely important physiological implications, but apart from STIM1, little is known about the actual protein participants in SOcAMPS. For example, how does the principal target of STIM1, Orai1, fit into this process? Are proteins related to STIM1, such as STIM2, involved? Another key question concerns how exactly cAMP is generated following store depletion.

Our previous studies using pharmacological agents excluded the involvement of the phosphodiesterases, the enzymes that degrade cyclic nucleotides, in SOcAMP signalling, but did implicate the enzymes that produce cAMP, the adenylyl cyclases (ACs). To date, nine closely related transmembrane isoforms of AC (tmAC1-9) and one soluble adenylyl cyclase (sAC or AC10) have been cloned and characterized \[[@b16]\]. Classically, tmACs are activated by heterotrimeric G--proteins in response to stimulation of G-protein coupled receptor. In contrast, the sAC is directly activated by cellular metabolites (CO~2~, bicarbonate and ATP), consistent with the role as an intracellular metabolic sensor \[[@b17]\]. A panel of different AC isoforms are generally coexpressed in a given cell type.

In this study, we used genetically encoded cAMP reporters in single NCM460 cells to define whether a singular isoform of adenylyl cyclase is responsible for store-dependent cAMP production in this cell type. We overcame the limitation imposed by the lack of pharmacological inhibitors for specific AC isoforms, and lack of suitable antibodies for protein chemistry by using overexpression and knockdown approaches to show a preferential link between the AC isoform AC3 in this store-operated process. In addition, although the presence of the plasma membrane Ca^2+^ entry channel Orai1 (or the STIM1 relative, STIM2) did not affect SOcAMPS, Ca^2+^ entering through this store-operated pathway did have a strong effect in terminating cAMP production. The physiological circumstances under which SOcAMPS is expected to become the predominant second messenger pathway following loss of ER Ca^2+^ stores are discussed.

Materials and methods
=====================

Reagents
--------

BAPTA-AM (1,2-bis([o]{.smallcaps}-Aminophenoxy)ethane-N,N,N′,N′-tetraacetic Acid Tetra(acetoxymethyl) Ester) was purchased from Molecular Probes/Invitrogen (Carlsbad, CA, USA), and ionomycin from Calbiochem (San Diego, CA, USA). Unless otherwise noted, all other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Cell culture
------------

NCM460 cells, a model of normal human colonic crypt epithelial cells \[[@b13]\] were obtained by licensing agreement from INCELL, San Antonio, TX, USA, and were grown in M3:10 medium (INCELL). For most experiments, NCM460 cells stably transfected with the FRET-based cAMP probe, CFP(nd)-EPAC(dDEP/CD)-YFP(nd) × pCDNA3 (H30) Amp or 'EpacH30' \[[@b18]\], were used. HeLa cells were grown in DMEM + 10% FCS; both lines were maintained in a humidified CO~2~ (5%) incubator at 37°C. Cells were split every 2 days after reaching 80% confluence.

Transfection with shRNA plasmids and siRNAs
-------------------------------------------

All siRNA tranfections were performed with Lipofectamine (Invitrogen) according to manufacturer\'s instructions, whereas plasmids were transfected using Effectene (Qiagen, Valencia, CA, USA). Briefly, 300 ng of the plasmid of interest plus 300 ng of mCherry (used as marker of transfected cells), were mixed in 180 μl of buffer reagent, to which 8 μl of Enhancer and 10 μl of Effectene reagent were added. After 20 min., the entire mixture was added to cells grown to 60--70% confluency into six-well plates.

For efficient knockdown of the different ACs we used a mix of four different HuSH 29mer shRNAs (500 ng of each plasmid per six-well plate) specific against AC3 or AC5. The pRFP-C-RS vector (Origene, Rockville, MD, USA) expressing the shRNAS also encodes the red fluorescent protein dsRED, used as a marker of transfected cells. As an alternative, we used siRNAs against AC3, AC5, AC6 and their effects were compared with that of non-effective siRNA 'scramble'. The day after transfection, cells were trypsinized and plated on glass coverslips, a step that resulted in a high proportion of isolated single cells in each microscope field, thereby minimizing gap-junction-mediated cAMP diffusion between cells \[[@b34]\].

Two days after transfection, imaging experiments were performed. In addition, total RNA was collected using RNeasy kit (Qiagen). One microgram of RNA was converted into cDNA using random hexamers (Invitrogen SuperScript First-Strand Synthesis System). Total AC3, AC5 and AC6 mRNA levels were calculated by Real-time RT-PCR using a TaqMan-based assays (Applied Biosystems, Carlsbad, CA, USA) and normalized to the endogenous 18S rRNA or GAPDH levels (amplified using a standard primer sets; Applied Biosystems) in three independent experiments.

Ratio Imaging of FRET-based cAMP sensors
----------------------------------------

Glass coverslips containing cells were mounted in a home-built flow-through perfusion chamber on top of the fluorescence imaging microscope stage as described previously \[[@b34],[@b52]\]. Two different FRET ratio imaging set-ups were used for this study: (i) a Nikon TE200 inverted fluorescence microscope equipped with a Photometrics QuantEM EMCCD camera, and (ii) a Nikon Eclipse TE2000-U microscope with attached Hamamatsu ORCA-ER CCD camera. Metafluor software (Molecular Devices, Sunnyvale, CA, USA) was used to control filter wheels (Sutter Instruments, Novato, CA, USA) in the excitation and emission paths and to control image acquisition (one image pair every 5--10 sec.) for both systems.

Cyclic AMP measurements were performed on single cells using the 480 nm/535 nm FRET emission ratio (440 nm excitation) of EpacH30 \[[@b18]\] and either a 40× Plan Fluor 1.30 NA or a 60× Plan Apo TIRF 1.45 NA oil-immersion objective. Cells were bathed in a HEPES-buffered Ringer\'s-like solution containing (in mM): 125 NaCl, 25 HEPES, 10 Glucose, 5 K~2~HPO~4~, 1 MgSO~4~ and 1 CaCl~2~, pH, 7.40. For Ca^2+^-free solutions (0 Ca^2+^), the CaCl~2~ was omitted and EGTA (25 μM) added to minimize contaminating Ca^2+^.

Statistics and analysis
-----------------------

Data are presented as mean ± S.E.M. Paired or unpaired Student\'s *t*-test was performed as appropriate to compare the means of two different groups of experiments. A value of *P* \< 0.05 was considered statistically significant. Analysis of the change in initial slope during the 2 min. following ionomycin addition was fitted by linear regression using Kaleidagraph software, and expressed as a percentage of the change in slope of the corresponding control response.

Results
=======

We observed previously that diverse strategies culminating in the lowering of free \[Ca^2+^\] within the ER resulted in cAMP production in NCM460 cells, measured using both a panel of FRET-based cAMP sensors and conventional cAMP immunoassays. These manoeuvres included: (i) inhibition of Ca^2+^ uptake by SERCA inhibitors (thapsigargin and tert-butyl hydroquinone), (ii) InsP~3~-dependent release of stores using native Ca^2+^ mobilizing agonists working through Gα~q~-coupled receptors (ATP and carbachol), (iii) buffering ER Ca^2+^ with high concentrations of membrane-permeant Ca^2+^ buffers (TPEN or BAPTA-AM), (iv) passive depletion of stores using high concentrations of EGTA, (v) treatment with Ca^2+^-mobilizing compounds such as bile acid (deoxycholic acid) or eicosapentaenoic acid and (vi) release of stores using Ca^2+^ ionophores such as ionomcyin.

To screen potential mediators or regulators of SOcAMPS, we developed a simplified protocol in which we released intracellular Ca^2+^ stores under Ca^2+^-free conditions using ionomycin in NCM460 cells stably expressing a FRET-based cAMP sensor, EpacH30 \[[@b18]\] (Fig. [1](#fig01){ref-type="fig"}A). This resulted in a reproducible increase in cAMP production (as measured by FRET ratio change of EpacH30) that was typically ∼35--40% of the maximal ratio change obtained following saturation of the cAMP sensor using forskolin (50 μM) and IBMX (1 mM). We also observed previously that this response to store depletion could be sustained for prolonged periods (measured longer than 60 min.), provided internal Ca^2+^ stores were kept in an empty state \[[@b4]\]. It should be emphasized that this increase in cAMP was absolutely independent of the initial transient spike in Ca^2+^ elicited by ionomycin-induced store release \[[@b4]\]. When cells were loaded with the Ca^2+^ buffer, BAPTA-AM (20 μM for 30 min.; conditions shown to eliminate the initial spike of cytosolic Ca^2+^ in NCM460 cells following ionomycin treatment, as measured by fura-2 in Ca^2+^-free solutions), the increase in the FRET ratio following store release was not altered (Fig. [1](#fig01){ref-type="fig"}B), consistent with our previous findings that SOcAMPS is independent of cytosolic Ca^2+^. In fact, manoeuvres that caused Ca^2+^ to become elevated within the cytoplasm, such as re-addition of bath Ca^2+^, strongly inhibited SOcAMPS (Fig. [1](#fig01){ref-type="fig"}A), and this was fully reversible upon superfusion of cells with Ca^2+^-free solutions (not depicted). This effect of Ca^2+^ re-addition was slowed dramatically, but not eliminated in the BAPTA-AM pre-treated cells, consistent with the fact that Ca^2+^ entering from the extracellular space will eventually overwhelm the Ca^2+^ buffering capacity of BAPTA, resulting in elevation of free Ca^2+^ within the cytoplasm and inhibition of SOcAMPS. Note too, that these experiments indicated that alterations in cationic metals other than Ca^2+^ (e.g. Zn^2+^) \[[@b19]\] were likely not responsible for this effect as BAPTA-AM chelates many trace heavy metals. Moreover, the effect of ionomycin was not altered by pre-treatment with TPEN (N,N,N′,N′-Tetrakis-(2-pyridylmethyl)ethylenediamine; 10 μM), a membrane permeant compound that is extremely effective at scavenging heavy metals (not depicted; *n* = 4 expts/26 cells).

![Evaluation of possible players involved in SOcAMPs in NCM460 cells stably expressing EpacH30. (A) Effect of ionomycin (5 μM) in the absence of external Ca^2+^. Addition of 1 mM Ca^2+^ resulted in a reduction in the FRET ratio (typical of 5 exp./29 cells). At the end of all experiments forskolin (FSK; 50 μM) and IBMX (1 mM) were added to obtain a supramaximal FRET response. (B) Effect of ionomycin in cells pre-loaded with BAPTA-AM (20 μM, 30 min.; typical of 6 exp./49cells). (C) Knockdown by RNAi of the Orai1 channel did not alter the response to ionomycin, however, the inhibitory action of 1 mM Ca^2+^ was significantly reduced as compared with scramble controls (6 exp./33 cells). (D) Response to ionomycin in scramble controls (6 exp./97 cells). (E, F) Summary of experiments in C and D: (E) Amplitude (Δ) and slope of the ionomycin response expressed as percentage of the response in scramble controls. (F) Response to 1 mM Ca^2+^ expressed as a % of the ionomycin response in scramble and siOrai1-treated cells. (G) Effect of overexpression of Orai1 on the response to ionomycin (5 exp./25 mCherry cells/7 control cells). (H) Summary of Orai1 overexpression experiments. Amplitude and slope of the ionomycin response expressed as a percentage of the response in control cells. (I) Summary of Orai1 + STIM1 overexpression experiments. (5 exp./9 control cells/10 mCherry cells) \*\**P* \< 0.02, \*\*\**P* \< 0.0001.](jcmm0016-2715-f1){#fig01}

Orai channels and STIM2 are not required for SOcAMPS
----------------------------------------------------

We first examined how the presence of the major Ca^2+^ entry channel, Orai1, affected this process. Knockdown by RNAi of the channel did not alter the FRET response to store depletion compared with scramble controls (Fig. [1](#fig01){ref-type="fig"}C--E and Supp. [Fig. 1A](#SD1){ref-type="supplementary-material"}), but the inhibitory action of Ca^2+^ re-addition was dramatically attenuated in the absence of Orai1 (Fig. [1](#fig01){ref-type="fig"}F), showing that Ca^2+^ entry *via* store-operated pathways was important for this effect. These findings are consistent with the fact that ionomycin-elicited Ca^2+^ transport across the plasma membrane derives mostly from activation of store-operated Ca^2+^ entry, with a smaller component arising from the ability of the ionophore to act as a Ca^2+^ carrier \[[@b20]\].

Overexpression of Orai1 alone or STIM1 alone is known to cause only slight alterations in store-operated Ca^2+^ entry. However, it has been shown that the co-expression of STIM1 and Orai1 in a specific ratio can enhance the Ca^2+^ entry current known as 'I~CRAC~' as much as 103-fold, creating the so called 'monster' I~CRAC~ \[[@b21]--[@b23]\]. Overexpression of STIM1 alone \[[@b4]\], Orai1 alone (Fig. [1](#fig01){ref-type="fig"}G and H) or of STIM1 + Orai1 (Fig. [1](#fig01){ref-type="fig"}I) did not significantly enhance the amplitude of the FRET response to ionomycin, although we did note that co-expression of both Orai1 and STIM1 caused the rate of cAMP increase following store depletion to become slightly faster. Furthermore, no effect was observed when the related channel, Orai3, which is also expressed endogenously in NCM460 cells, or Orai3 + STIM1 were overexpressed (Supplemental [Fig. 1B and C](#SD1){ref-type="supplementary-material"}). The overexpresssion or knockdown of the STIM1 relative, STIM2, also had no major impact on store-dependent cAMP signalling (Supplemental [Fig. 2](#SD2){ref-type="supplementary-material"}).

The chief conclusion of the preceding is that Orai1 is not necessary for store-operated cAMP production, but Ca^2+^ entry through Orai1 does have a significant inhibitory action on SOcAMPS. We considered the Orai1-dependent sensitivity of SOcAMPS to Ca^2+^ entry as an important clue towards identifying the potential players in SOcAMPS. For example, all AC isoforms are actually inhibited by high (10--25 μM, i.e. non-physiological) \[Ca^2+^\] \[[@b24]\]. However, lower concentrations (0.2--0.6 μM), such as those attained during Ca^2+^ signalling events, can either activate or inhibit certain ACs. Ca^2+^ entry through store-operated Ca^2+^ channels is known in particular to have a strong impact on AC1 and AC8 (isoforms activated by Ca^2+^ *via* calmodulin) and AC5 and AC6 (directly inhibited by Ca^2*+*^) \[[@b25]--[@b29]\]. More controversial has been the role of Ca^2+^ and Ca^2+^-calmodulin on the modulation of AC3 activity, which, however, has been shown in some cell systems to be inhibited by CaM kinase II (CaMKII) \[[@b30],[@b31]\].

In our previous article, RT-PCR identified seven different ACs isoforms expressed in NCM460 cells (AC3, AC4, AC5, AC6, AC7, AC9 and sAC) \[[@b4]\]. Isoform-specific inhibitors for the different ACs are not generally available \[[@b32],[@b33]\], nor are specific antibodies that permit immunoprecipitation of many of the ACs with their potential interacting proteins. Our prior data showed that SOcAMPS was prevented by P-site inhibitors specific for tmACs, such as SQ22536, and was enhanced by forskolin, an activator of most tmAC isoforms, except AC9. We therefore focused our efforts on overexpression and silencing of AC3-AC7, but also tested sAC.

Overexpression of AC isoforms
-----------------------------

Plasmids coding each of the isoforms of interest were cotransfected one at a time with the marker mCherry in NCM460 cells stably expressing EpacH30. To confirm that the tmAC plasmids were expressed and working properly, control experiments in HeLa cells (which do not have SOcAMPS) showed that only in mCherry positive cells was it possible to visualize enhanced cAMP production when challenging the cells with low doses of forskolin (10 nM). Using the protocol illustrated in Figure [2](#fig02){ref-type="fig"}A, the FRET response to ionomycin was compared between mCherry-expressing and control cells in the same microscope field. Only single cells not touching other cells were analysed to avoid artefacts because of gap-junction-mediated cAMP transfer between cells \[[@b34]\].

![Overexpression of AC isoforms. (A) Overexpression of AC3; response to ionomycin in cells co-transfected with AC3 and mCherry (used as a marker for transfection) and in control cells. (B) Summary of experiments on AC isoforms. Amplitude and slope of the ionomycin response expressed as % of control response. AC3: 8 exp./20 control/26 mCherry cells; AC4: 9 exp./16 control/21 mCherry cells; AC5: 13 exp./26 control/25 mCherry cells; AC6: 11 exp./38 control/24 mCherry cells; AC7: 6 exp./25 control/16 mCherry cells; sAC: 4 exp./11 control/10 mCherry cells. (C) Effect of co-expression of AC3 and STIM1 on the response to ionomycin. (D) Summary of results of overexpression of AC isoforms and STIM1. The response to ionomycin is expressed as % of the response in control cells. AC3+ STIM1: 6 exp./22control/8 mCherry cells; AC5+ STIM1: 8 exp./8 control/8 mCherry cells; AC6+ STIM1: 10 exp./18 control/14 mCherry cells. \**P* \< 0.05, \*\**P* \< 0.02, \*\*\**P* \< 0.01.](jcmm0016-2715-f2){#fig02}

Only overexpression of AC3 was able to consistently increase both the amplitude (*P* \< 0.01) and slope (a measure of cAMP production velocity; *P* \< 0.05) of the ionomycin response. Data from the other ACs are summarized in Fig. [2](#fig02){ref-type="fig"}B, showing that the amplitude (but not the speed) was also somewhat enhanced by transfection with plasmids for AC5 and AC6. Interestingly, AC3 (but not AC5 or AC6) co-expressed with STIM1-mCherry produced an ionomycin effect that was markedly greater than AC3 alone (Fig. [2](#fig02){ref-type="fig"}C; summary data in Fig. [2](#fig02){ref-type="fig"}D), reminiscent of the 'monster' I~CRAC~ reported for Orai1 and STIM1 co-expression.

Knockdown of AC3, but not AC5 or AC6, attenuates SOcAMPS
--------------------------------------------------------

Based on our findings above, we next tested the effect of knocking down AC3, AC5 and AC6. We first used shRNA plasmids that also encode the red fluorescent marker, dsRed, allowing us to distinguish knockdown cells from control cells in the same microscope field. As illustrated in Fig. [3](#fig03){ref-type="fig"}A cells expressing dsRed and shRNA against AC3 gave significantly reduced responses to ionomycin compared to both neighbouring control cells and cells expressing a dsRed + scramble construct. As summarized in Fig. [3](#fig03){ref-type="fig"}B, this action was not observed for AC5 shRNA. It should be pointed out that the presence of dsRed produced a highly variable fluorescence artefact leading to a small downward shift in the FRET ratio of EpacH30. This might be because of green fluorescent maturation intermediates of dsRed or aggregate formation, but the comparison of ratio changes between shRNA for AC3 and the scramble control nevertheless showed a significant effect of knocking down AC3.

![Effect of knockdown of AC isoforms. (A) Response to ionomycin in cells expressing shRNA against AC3; dsRed was used as a marker for transfection with shRNA. (B) Summary of experiments in cells expressing dsRed and shRNA against AC3 (13 exp./16 cells), AC5 (Δ: 7 exp., 12 cells; slope: 6 exp./11 cells), and treated with scramble (Δ: 10 exp./16 cells; slope: 9 exp./15 cells). Amplitude and slope of ionomycin response are expressed as % of control response. (C) Response to ionomycin in cells treated with siRNA for AC3 compared with cells treated with scramble (average of 14 scramble and 12 dsRed cells) (D) Summary of experiments with cells treated with siRNA for AC3 (6 exp./80 cells), AC5 (7 exp./68 cells) and AC6 (8 exp./91 cells) expressed as % of the response in scramble cells (scramble controls for siAC3 and siAC5: 13 exp./126 cells; scramble controls for siAC6 16 exp./202 cells). (E) Summary of qPCR experiments. siRNA AC3: 3 independent experimental samples; siRNA AC5: 3 exp.; siRNA AC6: 2 exp. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](jcmm0016-2715-f3){#fig03}

These findings were further confirmed by examining FRET responses of populations of cells treated with siRNA for AC3, AC5 and AC6. Although all siRNA constructs were effective in knocking down their respective targets, only siRNA against AC3 was able to significantly reduce the amplitude of the ionomycin-induced ratio change (Fig. [3](#fig03){ref-type="fig"}C--E).

Rescue of SOcAMPS phenotype in HeLa cells
-----------------------------------------

We next tested whether the SOcAMPS phenotype could be rescued in HeLa cells by simply overexpressing AC3, AC5 or AC6. Although there was generally no effect of introducing these ACs into these cells (Supplemental [Fig. 3](#SD3){ref-type="supplementary-material"}), even when inhibiting PDE activity with IBMX, it should be noted that there were occasional HeLa cells that gave a credible response to ionomycin after transfection with AC3 (2/11 transfected cells in three experiments) or AC3 + STIM1 (10/45 transfected cells in *n* = 8 experiments), but not STIM1 alone. The reasons for this inconsistency are unknown, but this could suggest that there is an unknown factor required to reconstitute the SOcAMPS phenotype that is intermittently expressed in HeLa cells.

Effects of PTX, CaMKII and PKC inhibitors on SOcAMPs
----------------------------------------------------

NCM460 cells pre-incubated for 18 hrs with pertussis toxin (PTX; 200 ng/ml) yielded typical responses to ionomycin treatment (78/79 cells in *n* = 9 expts). This indicates that PTX-sensitive Gα~i~-dependent signalling is not required for the initiation of SOcAMPS.

AC3 has been reported to be a target of CaMKII and PKC \[[@b24]\]. Thus, we questioned whether SOcAMPS might also be affected by pharmacological modulation of these two kinases. As shown in Fig. [4](#fig04){ref-type="fig"}A, acute treatment with the CaMKII inhibitor KN-62 (10 μM) after SOcAMPS had been initiated by ionomycin caused a slight enhancement of the response. However, treatment of NCM460 cells with KN-62 in the absence of ionomycin also caused a comparable elevation of the baseline FRET ratio. Although KN-62 did not prevent the subsequent cAMP response when ER stores were depleted with ionomycin (Fig. [4](#fig04){ref-type="fig"}B), the amplitude of the response was partially inhibited.

![Effects of CaMKII and PKC inhibitors. (A) Treatment with KN-62 (10 μM) after ionomycin (average of 25 cells), typical of 8 exp./115 cells. (B) KN-62 added before ionomycin (average of 16 cells); typical of 4 exp./44 cells. (C) 100 nM PMA added before ionomycin (average of 20 cells); typical of 5 exp./95 cells. (D) Effect of 100 nM PMA added during the response to ionomycin (average of 18 cells); typical of 6 exp./93 cells.](jcmm0016-2715-f4){#fig04}

Similarly, acute addition of the PKC activator PMA (phorbol 12-myristate 13-acetate; 100 nM) caused minor increases in the FRET ratio by itself, but did not prevent the subsequent response to ionomycin (Fig. [4](#fig04){ref-type="fig"}C). PMA, like KN-62, also slightly augmented the FRET ratio when added on top of ionomycin (Fig. [4](#fig04){ref-type="fig"}D). Long-term pre-treatment with 100 nM PMA (15 min., 3 and 12 hrs), conditions expected to down-regulate PKC activity, also did not abolish SOcAMPS (see Supplemental [Fig. 4](#SD4){ref-type="supplementary-material"} for summary of data at 15 min. and 3 hrs time points). From these data, we can conclude that neither CaMKII nor PKC serve as the mediators linking store depletion to cAMP production, although both of these effectors can slightly modulate cAMP signalling in NCM460 cells, as might be expected from a process mediated by AC3.

Discussion
==========

Most cells express not one, but rather a panel of multiple AC isoforms \[[@b35]\], the coexistence of which was formerly considered redundant. However, the striking phenotypes of isoform-specific knockout animals and of humans with polymorphisms and mutations in AC genes have revealed highly specialized physiological functions for the various ACs \[[@b16]\]. For example, AC5 is largely expressed in heart and brain, and when silenced in mice, prolongs lifespan and protects against stress \[[@b36]\]. AC6 is also expressed in heart, yet the deletion of AC6 compromises left ventricular function in a manner that is not replicable by eliminating AC5 \[[@b37]\]. Meanwhile, AC8 has been demonstrated to be a modulator of anxiety \[[@b38]\], whereas sAC is involved in male fertility, as mice lacking this gene have defects in sperm motility \[[@b39]\]. AC1, AC5, AC6 and AC8 have been reported to be uniquely susceptible to 'superactivation', a form of sensitization seen in model systems of drug withdrawal and recovery \[[@b32],[@b40]\].

Of note are the dramatic phenotypes associated with knocking down AC3, which in mouse induces an obese phenotype \[[@b41]\]. Ablation of AC3 also leads to alterations in murine maternal behaviour \[[@b42]\] that are likely related to defects in olfaction \[[@b43]\]. Genome-wide association studies have linked AC3 to the genetic aetiology of major depressive disorder \[[@b44]\]. Interestingly, in mouse hippocampal and cortical neurons, AC3 is localized exclusively to the primary cilium, where it generates a cAMP signal that is essential for certain types of learning and memory such as novel object recognition and contextual fear extinction \[[@b45]\].

The collective evidence presented here indicates that store-operated cAMP production occurs preferentially *via* AC3 in NCM460 colonic epithelial cells. It is noteworthy that recent data from Spirli and colleagues implicated AC6 as the likely source of cAMP in mouse cholangiocytes during SOcAMPS \[[@b15]\]. However, although some of our overexpression experiments suggested that AC5 and AC6 might also participate in this process, AC3 was the only isoform to consistently yield positive results in both overexpression and knockdown studies. Concurrent expression of AC3 plus STIM1 produced an even larger change in cAMP in response to store depletion. AC3 is the dominant AC in NCM460 cells (as measured by mRNA), but is widely expressed in other cell types and tissues, including at least one cell type that does not exhibit SOcAMPS, the HeLa cell. Moreover, overexpression of AC3 (or AC3 + STIM1) in HeLa cells did not consistently rescue the SOcAMPS phenotype. Therefore, the presence of AC3 is likely not a unique factor that defines SOcAMPS, and other, as yet unidentified, components of the pathway must exist.

Lowering of free ER \[Ca^2+^\] leads to dissociation of Ca^2+^ from the luminal EF hand domain of STIM1, which drives the clustering of STIM1 and Orai1 into aggregates at closely apposed junctions between ER and plasma membrane. The recruitment of other plasma membrane proteins (e.g. STIM2, L-type channels, TRP family members etc.) to this complex has also been described. Because of the dependence of SOcAMPS on the expression of STIM1, we similarly envisioned a scenario in which Orai1, by virtue of its physical interaction with STIM1, might serve to stabilize a complex of AC3-STIM1-Orai1 at the plasma membrane after ER \[Ca^2+^\] was reduced. However, the expression level of Orai1 (or Orai3 or STIM2, which are also abundant in NCM cells) did not affect cAMP production following store depletion. Unfortunately, we were unable to determine whether there might be a physical linkage between AC3 and STIM1 during SOcAMPS, because of the lack of suitable antibodies for immunoprecipitation of AC3. We also could not find any evidence for clustering of a GFP-tagged AC3 \[[@b46]\] into punctae following store depletion (Hofer and Maiellaro, unpublished). Thus, the nature of the interaction between STIM1 and AC3 during SOcAMPS remains to be determined.

Cooper and colleagues recently suggested a functional and perhaps physical connection between exogenously expressed AC8, a Ca^2+^-activated AC and Orai1 \[[@b47]\]. This intimate arrangement allows Ca^2+^ entering through Orai1 to potently activate AC8 in a localized microenvironment beneath the plasma membrane. Although Orai1 does not appear to be necessary for SOcAMPS, Ca^2+^ entering *via* this store-operated Ca^2+^ entry channel did reproducibly attenuate store-dependent cAMP production, although not completely eliminating it. The mechanism whereby Ca^2+^ exerts its inhibitory action is not known, and may be indirect. For example, using total internal reflection fluorescence (TIRF) microscopy of STIM1-YFP, we found that the translocation of STIM1 is diminished by high cytosolic \[Ca^2+^\] in NCM460 cells (A.M. Hofer, unpublished data), as it is in other cell types \[[@b48],[@b49]\].

The existence of a cAMP-generating pathway that is simultaneously activated by store depletion but inhibited by the concomitant store-dependent Ca^2+^ influx is unusual, but may provide some clues as to the function of SOcAMPS. In many cell types, Ca^2+^ signalling events elicited by physiological doses of agonists are oscillatory, with nominal release and refilling of the ER during each oscillatory cycle. Although the repetitive Ca^2+^ spiking in the cytosol may be optimally tuned to activate Ca^2+^ effectors, this type of ER depletion will not be of sufficient duration to elicit SOcAMPS. On the other hand, strong agonist stimulation typically results in profound ER store depletion sufficient to activate SOcAMPS, but also elicits robust Ca^2+^ entry through Orai channels, and this would attenuate cAMP production. Although such signals are normally terminated quite effectively by removal of the initiating stimulus, during persistent Ca^2+^ signalling Ca^2+^ entry can eventually become down-regulated, for example *via* feedback phosphorylation of Orai1 by Ca^2+^-dependent PKC \[[@b50]\]. Under such conditions, SOcAMPS would then become the dominant second messenger pathway. ER Ca^2+^ stores are also vulnerable to wide variety of environmental stressors, toxic insults, drugs, and viral and bacterial pathogens that cause unregulated, even permanent, loss of ER Ca^2+^. We propose that the unorthodox mode of AC3-dependent cAMP production described here may signal the initiation of adaptive responses (such as cAMP-dependent fluid secretion \[[@b51]\] or compensatory programmes of gene expression) in the face of persistent non-physiological loss of ER Ca^2+^ stores. Certain cell types (e.g. colon and airway epithelia) are at the frontline in the barrier against these noxious agents, and perhaps not coincidentally, are the same cell types that manifest the SOcAMPS phenotype.
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###### 

Fig. S1 (A) WESTERN BLOT showing effectiveness of Orai1 shRNA knockdown strategy. Bands were resolved in 5--20% tris-glycine gels and evidenced using Orai-1 primary antibody (1:500, Santa Cruz) followed by secondary anti-rabbit antibody (1:1000, Santa Cruz). (B) Bar graph summarizing effects of overexpression of Orai3 or (C) Orai3 + STIM1 in NCM460 cells. Cells expressing an Epac-based cAMP sensor plated onto glass coverslips were co-transfected with Orai3 or Orai3 + STIM1 together with mCherry (used as marker of transfected cells; 300 ng each). Forty-eight hours after transfection the coverslips were mounted in a home-built flow through perfusion chamber and imaged using a 60× oil immersion objective. Overexpression of Orai3 or Orai3 + STIM1 did not significantly alter ionomycin-induced cAMP production compared to control cells.

###### 

Fig. S2 (A) STIM2 is not required for store-operated cAMP signaling. Validation of three different strategies used for STIM2 silencing: (i) Dharmacon SmartPool (siRNA STIM2-a), (ii) Ambion silencer (siRNA STIM2-b), and (iii) Origene shRNA (shRNA STIM2). NCM460 or HeLa cells were transfected with 100nM siRNA or with 0.375 ng/μl of a plasmid expressing a single shRNA. Forty-eight hours after transfection, cells were lysed in RIPA buffer (Sigma-Aldrich) complemented with protease inhibitors (Sigma-Aldrich). Five to 10 μg of total cell lysate were resolved in 5--20% tris-glycine gels and electroblotted in PVDF membranes (Amersham Biosciences). The membranes were incubated for 2 hrs at room temperature with an anti-STIM2 polyclonal antibody (ProSci) diluted 1:500 in 5% milk/TBST. After washing with TBST membranes were incubated for 1 hr with secondary antibodies (1:2000; Santa Cruz). Peroxidase activity was detected with the enhanced chemiluminescence kit (Amersham Biosciences, ECL advance western blotting). Loading control, Glyceraldehyde-3-phopshate dehydrogenase (GAPDH; Santa Cruz 1:2000). (B) NCM460 cells expressing an Epac-based cAMP sensor plated onto glass coverslips were transfected with 100 nM of siRNAs against STIM2 (siRNA-a or siRNA-b) or their respective scramble siRNAs. Alternatively cells were co-transfected with shRNAs targeting STIM2 (or non-effective scramble) together with mCherry (used as marker of transfected cells). Forty-eight hours after transfection the coverslips were mounted in a home-built flow through perfusion chamber and cells were imaged using a 60× oil immersion objective. Initial experiments using a pool of four distinct siRNAs against STIM2 (siRNA-a, B-first bars) suggested that STIM2 attenuates SOcAMPs (data from 33 cells of scramble in 6 experiments; 73 cells siRNA STIM2 in 7 experiments; *P* \< 0.0005). However, the scramble control was not typical, thus this series of experiments was inconclusive. Numerous subsequent experiments using either the same siRNA pool (siRNA-a) (data from 21 cells of scramble in 4 experiments; 16 cells siRNA STIM2 in 3 experiments) or two alternative strategies, a single siRNA (siRNA-b) (data from 18 cells of scramble in 4 experiments; 18 cells siRNA STIM2 in 4 experiments) or a single shRNA against STIM2 (shRNA-C) (data from 10 cells of scramble in 4 experiments; 5 cells siRNA STIM2 in 4 experiments) led to the conclusion that STIM2 is not a significant constituent of the SOcAMPs machinery in NCM cells.

###### 

Overexpression of AC3 (*n* = 3 expts, 3 control cells and 9/11 mCherry cells), AC5 (*n* = 3 expts, 12 mCherry cells and 21 control cells), or AC6 (*n* = 3 expts, 27 control cells and 8 mCherry cells) in HeLa cells did not generally rescue the SOcAMPS phenotype. Shown is a typical result for AC3 overexpression. HeLa cells stable expressing Epac-H90 cyclic AMP based sensor were transfected the day after plating with the 300 ng AC isoform of interest plus 300 ng of mCherry plasmid. Experiments were performed 48 hrs after transfection.

###### 

Left panel: Summary of data from Fig 4C and D in main text. Addition of PMA alone to NCM460 cells caused a minor increase in the FRET ratio (expressed as a percentage of the maximal response following treatment with forskolin + IBMX; from experiments like Fig. 4C in main text). Addition of PMA after ionomycin caused a minor elevation in the FRET ratio compared to ionomyicn alone (refer to Fig. 4D in main text). Right panel: Amplitude of ionomycin response (expressed as a percentage of the maximal FRET ratio change following treatment with forskolin + IBMX) after 15 min. and 3 hrs treatments with PMA.
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